MT Newswires
Anixa Biosciences Says Breast Cancer Vaccine Candidate Meets Key Endpoints in Phase 1 Trial
β
AI Sentiment
Neutral
5/10
Latest updates and market news for ANIX
AI Sentiment
Neutral
5/10
AI Sentiment
Highly Positive
9/10
AI Sentiment
Neutral
5/10
AI Sentiment
Highly Positive
9/10
AI Sentiment
Highly Positive
8/10
AI Sentiment
Highly Positive
8/10
AI Sentiment
Highly Positive
8/10
AI Sentiment
Positive
7/10
AI Sentiment
Highly Positive
8/10
Share this news page